GSK says hepatitis B drug cured one fifth of patients in late-stage trials

Drug candidate bepirovirsen delivered a functional cure rate for 19% of patients in what the company sees as a breakthrough ...
Fierce Biotech

GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease

After treatment with bepirovirsen, however, 19% of patients achieved the strictly defined “functional cure” criteria. For the ...

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

By Bhanvi Satija LONDON, May 28 (Reuters) - GSK said its experimental chronic hepatitis B drug helped nearly one in five ...

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

The findings supporting bepiroversen were deemed a “historic moment” by physicians and validate a drug that has “clear ...

GSK Adds Shares to Market Under Employee Save Plan

GSK has admitted 45,273 new ordinary shares of 31¼ pence each to trading on the London Stock Exchange’s Main Market under its existing block listing for the GlaxoSmithKline plc Share Save Plan 2022.
BioSpace

GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients

The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for ...
Sky

Unilever shares rise as it rules out increasing its £50bn consumer healthcare takeover offer to GSK

Shares in consumer goods giant Unilever have risen after it effectively ended its pursuit of GlaxoSmithKline's consumer healthcare business saying it would not raise its £50bn offer. GSK revealed over ...
Pharmabiz

GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA

GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA: London, UK Thursday, May 28, 2026, 10:00 Hrs [IST] GSK plc will present ne ...

GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading

Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that unanswered commercial questions mean any ...

GSK (LSE:GSK) Valuation Check After Recent Share Pullback And Stronger One Year Return

How GSK’s recent performance frames the stock today GSK (LSE:GSK) has recently drawn attention after a period of mixed share performance, with the stock down about 2% over the past month and about 15% ...
The Independent

Unilever won't top $68B bid for GSK consumer healthcare unit

Unilever, the maker of Vaseline skin care products and Dove soap, says it won’t increase a 50 billion-pound ($68.2 billion) offer for GlaxoSmithKline’s consumer healthcare unit that was rejected last ...

See what £13,000 invested in GSK shares 3 months ago is worth today…

Harvey Jones was thrilled with the performance of his GSK shares, but lately it's all gone a bit flat. Could the recent dip be a buying opportunity? The post See what £13,000 invested in GSK shares 3 ...